Weight Loss
Single Agonist vs Dual Agonist vs Triple Agonist: Which Generation of Obesity Drug?
The obesity drug class has evolved through three generations in the last decade. Single agonists like semaglutide target one receptor (GLP-1).
Retatrutide Real Results: Weight Loss Timeline & What Patients Report
Retatrutide’s Phase 2 trial produced the largest mean weight loss ever recorded in a GLP-1-class obesity study.
Plateau on GLP-1: When Weight Loss Stops and How to Restart
Almost everyone on a GLP-1 hits a plateau eventually. The question is when and what you can do about it.
What Percentage of Body Weight Do People Lose on GLP-1?
On average, people on semaglutide 2.4mg lose 14.9% of body weight at 68 weeks (STEP 1 trial, Wilding et al. 2021, NEJM).
Pemvidutide Real Results: Weight Loss Timeline & What Patients Report
Introduction Pemvidutide’s main efficacy dataset is the MOMENTUM phase 2 trial: 391 adults with obesity (mean BMI 37) followed for 48 weeks across three…
Pediatric GLP-1: Should Teenagers Take Weight Loss Medication?
In January 2023 the American Academy of Pediatrics released its first clinical practice guideline on childhood obesity in fifteen years.
Orforglipron Real Results: Weight Loss Timeline & What Patients Report
Orforglipron weight loss accumulates gradually over many months.
New Year’s Resolution GLP-1 Guide: Starting Weight Loss in January
January is the highest-volume start month for GLP-1 prescriptions.
Menopause and GLP-1: Managing Weight During Hormonal Changes
The 40s and 50s bring metabolic changes that frustrate even the most disciplined women.
